問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

呂宜達

Recruiting

List

27Cases

2020-05-01 - 2024-11-18

Phase I/II

Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infection

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Chimpanzee adenovirus HBV vaccine, 2.Modified Vaccinia Ankara HBV vaccine, 3.HBc-HBs/AS01_B4,

Participate Sites
5Sites

Recruiting5Sites

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

2019-03-01 - 2023-12-31

Phase III

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet; Atezolizumab 1200mg/ 20ml solution for IV infusion

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2019-11-01 - 2023-01-31

Phase II/III

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cance

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Bintrafusp alfa (M7824)

Participate Sites
7Sites

Recruiting7Sites

2015-07-01 - 2022-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Ramucirumab (Cyramza)

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

2024-01-01 - 2030-11-30

Phase II/III

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment –LIVIGNO-2

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Livmoniplimab (ABBV-151)；Budigalimab (ABBV-181)

Participate Sites
5Sites

Recruiting5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB